CasNo.654671-78-0,Sitagliptin phosphate,(654671-78-0) Suppliers

1 Kilogram	Negotiable

Min.Order :1 Kilogram
Purity: 98%
Payment Terms : L/C,D/A,D/P,T/T,

Keywords

654671-78-0 Sitagliptin phosphate C13H13ClN2O

Quick Details

Appearance:White or off-white Solid
Application:Organic synthesis
PackAge:According to the demand of customer
ProductionCapacity:20|Metric Ton|Month
Storage:Sealed, dry, microtherm , avoid light and smell.
Transportation:by air or by sea

Superiority:

high quality

Details:

Located in Zhengdong New District, Zhengzhou of Henan province, Henan Allgreen Chemical Co.,Ltd is comprehensive high-tech modern enterprises integrating professional R&D, production and sales. Strong technical force, with a long-term professional development team engaging in the fine chemicals, Henan Allgreen Chemical Co.,Ltd is mainly engaged in development and customized of organic electronic chemical materials, metal catalysts, phosphorus ligands, medical intermediate , chemical reagent and other fine chemical products.We have multifunctional production conditions and could offer high quality products from grams to kilograms and tons. In addition, we absorb new technology actively from colleges and also have established good relations of cooperation with Huazhong University of Science and Technology ,Henan Institute of Engineering and some other well-known domestic enterprises. Our products have been exported to Japan, South Korea, Europe, America and other countries and regions, well received by customers.

With sound management system, we've been authorized the Import&Export qualification by the government and also has passed the “ISO 9001-2008 Quality Management System” certification. We always stand on the quality of product as our life, develop in the direction of customers requirement and aim at creating greater value for customers.Innovation and honesty, we will make common development with the masses of customers at home and abroad hand in hand by our best service.

Sitagliptin phosphate Basic information

New antidiabetic drug DPP-4 inhibitors

Product Name:	Sitagliptin phosphate
Synonyms:	4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate;Sitagliptin phosphate;7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-α]pyrazine-phosphate;(3R)-3-aMino-1-[3-(trifluoroMethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;Sitagliptin phosphate/Sitagliptin phosphate Monohydrate/Sitagliptin;Sitagliptin phosphate 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate
CAS:	654671-78-0
MF:	C16H15F6N5O.H3PO4
MW:	505.31
EINECS:
Product Categories:	All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API;Pharmaceutical intermdiate
Mol File:	654671-78-0.mol

Sitagliptin phosphate Chemical Properties

mp	202-204°C
storage temp.	-20°C Freezer

Safety Information

MSDS Information

Sitagliptin phosphate Usage And Synthesis

New antidiabetic drug	Sitagliptin phosphate is dipeptidyl peptidase Ⅳ(DDP-4) inhibitor class of drugs developed by the German Merck company and firstly obtained the US Food and Drug Administration approval for the treatment of type 2 diabetes, is a new antidiabetic drug, can improve the body's own ability to reduce high blood glucose levels, and the relatively increase naturally occurring incretin by inhibiting the activity of this enzyme, including the levels of glucagon-like peptide 1 and glucose-dependent insulinotropic peptide, thereby triggering the pancreas to improve insulin production and stop glucose production in liver, and ultimately reduce the clinical effect of blood glucose concentration. Features of this product is to stimulate insulin secretion, at the same time can alleviate hunger, but does not make weight gain, and also cannot happen hypoglycemia and edema, is not suitable for use in diabetic patients with poor glycemic control and often developed hypoglycemia. By verification of clinical 552 cases of mild to moderate type 2 diabetes, taken once a day Sitagliptin phosphate, once time 100 mg, after taking the drug for 12 weeks, can make glycated hemoglobin reduce 0.6% -1.1%. Incidence of adverse reactions is similar to placebo, the most frequently reported adverse reactions (incidence> 5% and greater than placebo) is a stuffy or runny nose, and sore throat, upper respiratory tract infection and headache. Clinical studies showed that the Sitagliptin phosphate as monotherapy in patients with type 2 diabetes, can make glycated hemoglobin (HbA1c) levels significantly reduce. When in combination with the metformin or TZDs, has a significant role of adjuvant therapy, can focus on three kinds of major defect in type 2 diabetes: insulin resistance, β-cell dysfunction (reduction of insulin release), and α-cell dysfunction (unsuppressed hepatic glucose generation) plays a role. But the drug should not be used for treatment of patients with type 1 diabetes or diabetic ketoacidosis. The above information is edited by the chemicalbook of Liu Yujie.
DPP-4 inhibitors	Sitagliptin phosphate (trade name Januvia) is the DPP-4 inhibitor first clinically approved for the treatment of type 2 diabetes, developed by Germany company Merck, and was listed in 2006 in Mexico and the United States in 2007, also obtained EU approval for the treatment of type 2 diabetes. China approval was soon, currently Sitagliptin phosphate tablets has become the second largest drug of oral diabetes drugs in US. Sitagliptin phosphate can enhance a called incretin system of human physiological system, resulting in physiological hypoglycemic effect. This physiological system itself can affect β cells and α cells of the islet, help to regulate glucose, and insulin reduction only caused by β-cell dysfunction can cause the increase of blood glucose, or because cells α and β-cell dysfunction cause loss of control in hepatic glucose synthesis and thus lead to elevated blood glucose, DPP-4 will produce efficacy. Sitagliptin phosphate exists dependent of glucose levels, it will not only know hypoglycemic blindly, not predatorily press islet, exhaust the pancreas function. In contrast, the test proved that it has the prospect of long-term protection of human β cells. In addition, it does not lead to side effects such as weight gain, decreased blood glucose, medication compliance of patient will be greatly enhanced. Therefore, in theory it's effective role in life will greatly exceed the current oral antidiabetic drug, insulin dependent of patients will be greatly delayed.
Chemical Properties	White Solid
Usage	A trizolopyrazine dipeptidyl peptidase IV inhibitor. It has recently been approved for the therapy of type II diabetes.
Usage	Sitagliptin is a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has recently been approved for the therapy of type II diabetes.